ArticleHuman vaccines & immunotherapeutics2025
Seroprevalence and determinants of SARS-CoV-2 anti-nucleocapsid IgG in a vaccinated Iranian adult population: A cross-sectional study, Summer 2023.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-nucleocapsid (anti-N) IgG serology is increasingly used to distinguish natural SARS-CoV-2 infection from vaccine-induced immunity. However, post-vaccination seroepidemiological data from highly immunized Middle Eastern populations remain limited. We assessed anti-N IgG seroprevalence and its predictors in a cohort of Iranian adults during the summer of 2023. A total of 251 individuals aged 18-65 years were enrolled through community outreach at Gholhak Laboratory, a high-throughput diagnostic center in Tehran. Participants completed structured questionnaires that captured demographic characteristics, COVID-19 vaccination history (vaccine platform, dose count, and time since last dose), smoking status, occupation, pregnancy status, and prior COVID-19-related hospitalization. Anti-N IgG levels were measured using a commercial ELISA (Pishtaz Teb, Tehran, Iran); seropositivity was defined by a signal-to-cutoff ratio ≥ 1.1. Prevalence ratios (PRs) were estimated via Poisson regression with robust variance, adjusting for covariates including age, gender, BMI, smoking, and vaccination characteristics. The overall anti-N seroprevalence was 55.8% (95% CI: 49.7-61.7). Seropositivity was significantly associated with female gender (PR for males 0.70,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.